The regulator pointed out deficiencies at the manufacturing facility. Credit: Gorodenkoff/Shutterstock.com. The US Food and Drug Administration (FDA) has rejected Alvotech’s biologics licence application (BLA)
Bristol Myers Squibb will utilise the programme to assess the Cell Shuttle platform as an automated manufacturing process. Credit: Tada Images/Shutterstock.com. Cellares has entered an
IMIDomics will utilise the technology and expertise of the University of Barcelona to progress its drug targets through research projects. Credit: Gorodenkoff/Shutterstock.com. IMIDomics has entered
Gritgen will begin production of its Phase III clinical and commercial product for haemophilia A. Credit: Sergey Kolesnikov/Shutterstock.com. Gritgen Therapeutics has launched operations at its
Oregovomab is intended for the treatment of advanced ovarian cancer. Credit: Chinnapong/Shutterstock.com. CanariaBio has entered into a distribution and licence agreement with Hikma MENA FZE,
Smyraf is intended for the treatment of rheumatoid arthritis. Credit: BlurryMe/Shutterstock.com. Menarini Asia-Pacific has entered a long-term exclusive agreement to license Astellas Pharma’s Smyraf to
Eywa’s facility boasts the potential for a capacity expansion of up to two billion tablets or capsules annually. Credit: mkfilm/Shutterstock.com. Biocon’s step-down, wholly owned subsidiary,
Reset Pharma will use PEX010 in a Phase II clinical trial. Credit: Maxim Shmelyev/Shutterstock.com. Reset Pharmaceuticals has entered a licensing agreement with Filament Health for
Repotrectinib is intended to treat NTRK-positive advanced solid tumours. Credit: Motortion Films/Shutterstock.com. China’s National Medical Products Administration’s Center for Drug Evaluation has granted breakthrough therapy
The combined company will focus on advancing Serina’s SER-227 for treating advanced Parkinson’s disease. Credit: Ground Picture/Shutterstock.com. US-based clinical-stage biotechnology company Serina Therapeutics has entered